[go: up one dir, main page]

AU2545397A - Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives - Google Patents

Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives

Info

Publication number
AU2545397A
AU2545397A AU25453/97A AU2545397A AU2545397A AU 2545397 A AU2545397 A AU 2545397A AU 25453/97 A AU25453/97 A AU 25453/97A AU 2545397 A AU2545397 A AU 2545397A AU 2545397 A AU2545397 A AU 2545397A
Authority
AU
Australia
Prior art keywords
pyrimidines
arylthio
aryloxy
derivatives
fused pyridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU25453/97A
Other versions
AU725254B2 (en
Inventor
Rajagopal Bakthavatchalam
James Peter Beck
Robert John Chorvat
Paul Joseph Gilligan
Richard Eric Olson
Parthasarathi Rajagopalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2545397A publication Critical patent/AU2545397A/en
Application granted granted Critical
Publication of AU725254B2 publication Critical patent/AU725254B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU25453/97A 1996-03-26 1997-03-25 Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives Ceased AU725254B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1409096P 1996-03-26 1996-03-26
US60/014090 1996-03-26
US64661196A 1996-05-08 1996-05-08
US08/646611 1996-05-08
PCT/US1997/004828 WO1997035846A1 (en) 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Publications (2)

Publication Number Publication Date
AU2545397A true AU2545397A (en) 1997-10-17
AU725254B2 AU725254B2 (en) 2000-10-12

Family

ID=26685647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25453/97A Ceased AU725254B2 (en) 1996-03-26 1997-03-25 Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives

Country Status (6)

Country Link
EP (1) EP0901476A4 (en)
JP (1) JP2000507552A (en)
AU (1) AU725254B2 (en)
CA (1) CA2249598A1 (en)
NZ (1) NZ331647A (en)
WO (1) WO1997035846A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
ES2196898T3 (en) 1998-11-12 2003-12-16 Neurocrine Biosciences Inc ANTAGONISTS OF CRF RECEIVERS AND RELATED METHODS.
IL142893A0 (en) 1998-11-12 2002-04-21 Neurocrine Biosciences Inc Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CA2419626A1 (en) * 2000-07-14 2002-01-24 Rajagopal Bakthavatachalam Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders
BR0208357A (en) 2001-03-13 2004-06-29 Bristol Myers Squibb Pharma Co Compound, pharmaceutical composition, corticotropin-releasing factor (crf) receptor antagonization method, dysfunction treatment method, ligand screening method, crf receptor detection method, crf binding inhibition method, article industrialized and uses of compost
PL366577A1 (en) 2001-05-14 2005-02-07 Bristol-Myers Squibb Pharma Company Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
US6894045B2 (en) 2001-07-12 2005-05-17 Bristol-Myers Squibb Pharma Company Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2003043637A1 (en) 2001-11-20 2003-05-30 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
KR20210061202A (en) * 2019-11-19 2021-05-27 일동제약(주) Benzonitrile-substituted Fused pyrimidine derivatives and their pharmaceutical use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
JPS56131586A (en) * 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS56131587A (en) * 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS5962595A (en) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd 3,5,7-trisubstituted-triazolopyrimidine derivative and its preparation
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
DE3722802A1 (en) * 1987-07-10 1989-01-19 Hoechst Ag 2-AMINO-8-AZA PURINS SUBSTITUTED IN 6 AND 9 POSITIONS, THEIR USE, MEDICINAL PRODUCTS CONTAINING THESE PURINES AND METHOD FOR THE PRODUCTION OF THE PURINS
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB9011623D0 (en) * 1990-05-24 1990-07-11 Efamol Holdings Synthesis of nucleotide and nucleoside derivatives
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
CN1142817A (en) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
GB9400987D0 (en) * 1994-01-19 1994-03-16 Reese Colin B Production of nucleoside analogues
CA2192208C (en) * 1994-06-06 2002-09-10 Pfizer Limited Substituted pyrazoles
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
CN1056611C (en) * 1994-06-16 2000-09-20 美国辉瑞有限公司 Pyrazolo and pyrrolopyridines
PT778277E (en) * 1995-12-08 2003-11-28 Pfizer HETEROCYCLIC DERIVATIVES SUBSTITUTED AS CRTA ANTAGONISTS

Also Published As

Publication number Publication date
EP0901476A4 (en) 2001-08-16
EP0901476A1 (en) 1999-03-17
AU725254B2 (en) 2000-10-12
NZ331647A (en) 2000-03-27
WO1997035846A1 (en) 1997-10-02
JP2000507552A (en) 2000-06-20
CA2249598A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
PL335258A1 (en) Arylamine-condensed pyridines and pyrimidines
AU4383397A (en) Hetaroyl derivatives
AU4554297A (en) Hetaroyl derivatives
IL131521A0 (en) Pyrimidine derivatives
AU2303097A (en) Quinazoline derivatives
AU1252897A (en) Substituted quinazoline derivatives
AU2897897A (en) Aryl pyrimidine derivatives
AU5759999A (en) Pyrimidone derivatives
AU3008297A (en) Dihydropyrimidines and uses thereof
AU5135998A (en) Novel urea derivatives
AU2844897A (en) Bicyclic-fused pyridines
AU7687298A (en) Dihydropyrimidines and uses thereof
AU1411499A (en) Para-aminomethylaryl carboxamide derivatives
HK1026418A1 (en) Novel pyrimidine derivatives and processes for the preparation thereof
ZA971896B (en) Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
AU8885498A (en) Triazine derivatives, their production and use
AU2464197A (en) Triazine derivatives and their use
ZA972553B (en) Aryloxy-and arylthio- substituted pyrimidines and triazines and derivatives thereof
AU2545397A (en) Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives
AU9809698A (en) Substituted pyrimidine and pyridine herbicides
AU1415099A (en) 4-substituted-4-piperidine carboxamide derivatives
AU3486195A (en) Pyrimidinone derivatives
AU5923998A (en) 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
AU1687699A (en) Nitrogenous heterocyclic derivatives
HK1025955A1 (en) Novel pyrimidine derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired